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Abstract   
Opioid Use Disorder (OUD) is a chronic, relapsing condition, often associated with legal, 
interpersonal and employment problems. Medications demonstrated to be effective for OUD are 
methadone (a full opioid agonist), buprenorphine (a partial agonist) and naltrexone (an opioid 
antagonist). Methadone and buprenorphine act by suppressing opioid withdrawal symptoms, and by 
attenuating the effects of other opioids. Naltrexone blocks the effects of opioid agonists. Oral 
methadone has the strongest evidence for effectiveness. Longer duration of treatment allows 
restoration of social connections and is associated with better outcomes. Treatments for OUD may 
be limited by poor adherence to treatment recommendations, and high rates of relapse and 
increased risk of overdose after leaving treatment. Treatment with methadone and buprenorphine 
has the additional risk of diversion and misuse of medication. New depot and implant formulations 
of buprenorphine and naltrexone have been developed to address issues of safety and problems of 
poor treatment adherence. For people with OUD who do not respond to these treatments, there is 
accumulating evidence for supervised injectable opioid treatment (prescribing pharmaceutical 
heroin). Another medication mode of minimizing risk of overdose is take-home naloxone (THN). 
Naloxone is an opioid antagonist used to reverse opioid overdose, and THN programs aim to prevent 
fatal overdose. All medication-assisted treatment is limited by lack of access, and stigma. In seeking 
to stem the rising toll from OUD, expanding access to approved treatment such as methadone, for 
which there remains the best evidence of efficacy, may be the most useful approach.   
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Introduction - Medication Assisted Treatment  
Three medications are currently registered in the US (and many other jurisdictions) for use in 
Medication Assisted Treatment (MAT) of opioid use disorder (OUD). Most experience has been with 
methadone, which remains the gold standard against which other medications have been compared. 
Methadone is a full opioid agonist, producing dose-dependent analgesia, sedation. and risk of 
respiratory depression in overdose. It has a long but variable half-life, usually around 22 hours, but 
ranging 13-50 hours (1). Buprenorphine is categorised as a partial agonist at the mu-opioid receptor; 
it has a high affinity for the mu-opioid receptor; low doses produce typical opioid effects, but 
increasing doses prolong rather than increase opioid agonist effects (2). Naltrexone is a mu-opioid 
receptor antagonist, blocking the effects of opioids (and precipitating withdrawal if administered to 
a person currently dependent on opioids). It has been used clinically as an aid to sustaining 
abstinence, blocking the pleasurable effects of opioids and reducing the risk of relapse after 
impulsive use of opioids.  
 
Follow-up studies of people seeking treatment demonstrate that the course of OUD tends to be a 
chronic, relapsing one, particularly for people with poor social supports or mental health issues (3). 
Treatment of OUD does not fit an acute care paradigm, with the objective of cure, but is better 
conceptualised as the management of a chronic condition (4). Longer episodes of continuous 
treatment are associated with later, and a lower likelihood, of returning to treatment – a measure of 
relapse (5). The duration of methadone treatment has been demonstrated to be a linear, non-
threshold predictor of outcome (6); longer episodes of treatment are associated with better 
outcomes.   
  
Slowly tapering doses of methadone or buprenorphine have been used in medically managed 
withdrawal from opioids (“detoxification”). However, short-term abstinence is not predictive of long-
term remission (7). Given the consistent evidence of the importance of treatment duration, the 
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likelihood of relapse with treatment discontinuation, and increased risk of overdose after 
detoxification (8), offering medically managed withdrawal alone increases risks with uncertain 
benefit. A flexible approach to patients who request detoxification is to initiate MAT with the option 
of continuing or reducing slowly to abstinence, depending on patient's progress (9).   
 
The objectives of long-term management include reduced risk of death and disease, improvement in 
mental health and outlook, and restoration of social role impaired through such issues as 
unemployment, disrupted family relations, and involvement with criminal justice system (4). These 
objectives are most likely to be achieved if patients stop or markedly reduce their use of illicit 
opioids (10, 11). Most research on effectiveness of MAT has been undertaken with methadone. In 
suppressing the use of illicit opioids, methadone treatment is more effective than short-term 
treatment or no treatment (12). Methadone treatment attracts and retains in treatment more 
people with OUD than drug-free approaches (12,13). The suppression of illicit opioid use which 
follows entry to treatment results in a reduced risk of fatal overdose for as long as people remain in 
treatment (14,15). Reduction in crime (16,17), and subjective improvement in quality of life (18) also 
occur through reduced use of illicit opioids during methadone treatment.    
 
Premature dropping out of treatment is common, and people often cycle in and out of short 
episodes of MAT (19,20). In part, poor response to MAT is due to variations in treatment delivery, 
which often deviates from what has been demonstrated to be effective (21, 22). In particular, use of 
subtherapeutic doses of methadone and buprenorphine have compromised treatment effectiveness 
(23). The importance of adequate doses reflects the pharmacological mechanism of action of 
methadone and buprenorphine - suppressing opioid withdrawal, attenuating the effects of injected 
opioids, and protecting against overdose (23).  
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A single daily dose of 30mg methadone is sufficient to block the emergence of opioid withdrawal for 
at least 24 hours in most people with OUD (24). However, at this daily dose, many patients persist in 
injecting street opioids. Higher doses of methadone induce opioid tolerance, reducing the rewarding 
effect of injected opioids. A pooled review of randomised controlled trials reported that high dose 
(60-100mg/day methadone) was more effective in producing abstinence from non-prescribed 
opioids as detected by urine testing than was middle (40-60mg) doses or low dose (<40mg) (25). 
 
Buprenorphine at dose >8mg/day has been reported to suppress opioid withdrawal for 24 hours in 
opioid-dependent subjects (26). However, to suppress use of illicit opioids during treatment, higher 
doses of buprenorphine are more effective. Buprenorphine binds to opioid receptors, producing 
prompt blockade of other opioids. Positron Emission Tomography (PET) scanning indicates that 
buprenorphine 2mg produced 41% inhibition of carfentanil binding, 16mg produced 80% inhibition, 
and 32mg produced 84% inhibition (27). Consistent with these laboratory findings, a meta-analysis 
of published trials concluded that buprenorphine doses >16mg/day were more effective than doses 
<16mg at retaining subjects in treatment (28). 
 
An oral dose of 50mg naltrexone produces mu opioid receptor blockade lasting 24 to 36 hours. It is 
difficult to induct people onto naltrexone due to the need for a period of abstinence before initiating 
antagonist treatment; and once in treatment, there is a high rate of early discontinuation (29, 30). 
Methadone and buprenorphine produce “drug liking” responses in people with OUD, and people 
who miss doses experience opioid withdrawal. These responses contribute to holding people in 
treatment. Naltrexone produces no positive opioid effects, and this may contribute to erratic 
compliance, early drop-out and resulting increased risk of fatal overdose (31).  
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Safety of MAT 
Respiratory depression and overdose 
Methadone produces respiratory depression if administered to non-tolerant individuals. Methadone 
treatment involves inducing a higher level of tolerance than occurs during use of illicit drugs, and if 
the dose is raised too rapidly, respiratory depression, potentially fatal, results. During induction, the 
blood level achieved by a stable dose progressively increases over the first week, due to tissue 
binding and to methadone‘s long half-life. A dose which was tolerated on day 1 may produce fatal 
respiratory depression in non-tolerant patients on day 2 or 3. Clinical guidelines recommend 
methadone doses need to start low and be slowly increased to avoid fatalities in the first month of 
treatment (15). Increasing doses of buprenorphine produce little or no increase in opioid effects. 
This “ceiling effect” reduces the risk of respiratory depression in the event of overdose. Induction 
onto buprenorphine is associated with a significantly lower risk of overdose than induction onto 
methadone (15). 
 
While adhering to MAT, patients are at reduced risk of overdose; however, there is a significantly 
increased risk of fatal overdose in the month after leaving any form of treatment for OUD (5,15, 31). 
Benzodiazepine use is common among people with OUD, and concurrent use of benzodiazepines 
and methadone is associated with an increased risk of fatal overdose and emergency room (ER) 
presentations (32, 33). 
 
QT Interval prolongation  
Methadone prolongs the QTc interval, and high-dose methadone has been associated with the 
ventricular tachycardia “torsades de pointes” (34). This is rare complication, and there is little 
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consensus on the implications for treatment programs (35).  Buprenorphine appears to have 
minimal impact on the QTc (36). 
 
Diversion 
As prescribing of methadone or buprenorphine increases in a jurisdiction, there is an increase in 
overdose deaths from these drugs amongst people not in treatment (37). Some degree of diversion 
is inevitable when prescribing agonist medication (38), and much of the diverted mediation goes to 
people with OUD who are not in treatment. Measures to minimize diversion include ensuring good 
access to treatment, and administering doses under direct observation, restricting unsupervised 
doses to people who meet criteria of stability (38). There have not been reports of problems 
associated with diversion and misuse of naltrexone. 
 
In some countries (e.g. UK, Australia), methadone and buprenorphine are administered under direct 
observation. In these jurisdictions, both medications can be prescribed in primary care and 
dispensed (with observation) by community pharmacists. In the US and France, methadone is only 
available via clinic-based programs and administered mainly under direct observation, but 
buprenorphine can be prescribed by trained doctors, with medication not directly observed. This 
model of treatment is made possible because buprenorphine diversion is associated with 
significantly less risk of fatal overdose than is diverted methadone (39). Office-based treatment 
improves access, reduces stigma and requires less costly infrastructure.   
 
The provision of buprenorphine without supervised administration potentially risks diversion. An 
extreme example is that buprenorphine diverted from France created a black market in Georgia, 
where injected buprenorphine became the primary drug of abuse (40). A combination of 
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buprenorphine and naloxone has been marketed to minimize intravenous misuse. The rationale is 
that taken orally or sublingually, the naloxone has only low bioavailability whereas, if the medication 
is crushed and injected, naloxone attenuates the opioid agonist effect, and precipitates withdrawal 
in people dependent on opioids. There is conflicting evidence as to the effectiveness of the 
combination in deterring intravenous misuse; the added naloxone appears to reduce, but does not 
abolish, intravenous misuse (41). 
 
 
Comparing effectiveness of medications used in MAT 
Large-scale observational studies (15) and pooled analysis of randomised trials (12) concur that 
retention in buprenorphine is inferior to retention in methadone. The impact of differences in 
retention has been demonstrated in a large trial which randomised participants to methadone or 
sublingual buprenorphine-naloxone (BNx) at flexible doses (42). At 24 weeks, 74% remained on 
methadone, and 46% on BNx, a clinically and statistically significant difference. Doses higher than 
16mg BNx and >60mg of methadone were associated with fewer opioid-positive urine tests. Non-
prescribed opioid use was significantly lower among BNx than methadone participants during the 
first 9 weeks, but not thereafter. This reflects the pharmacological differences between the full 
agonist and partial agonist - methadone suppresses the response to illicit opioid use in a dose-
dependent and time-dependent fashion, through the progressive development of tolerance (43), 
whereas buprenorphine promptly occupies mu receptors and produces a degree of receptor 
blockade. However, the benefits of early suppression of illicit opioid use were offset by poor 
retention. Even with the highest BNx dose level of 30–32mg, the retention rate was less than the 
rate in the methadone group, and approximately 30% of the participants continued illicit opioid use. 
Significantly more BNx participants left the trial because they no longer wished to participate in their 
assigned treatment (25.6% vs. 12.4%, p< .001).  
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A qualitative study of a subset of participants in this trial (44) reported that for some, withdrawal 
symptoms or negative reactions continued beyond the induction period, despite dosage 
adjustments. Some participants reached a dose of 32 mg but continued to feel sick. These results are 
consistent with findings from a double-blind, double-dummy comparison of methadone and 
buprenorphine (45), in which respondents on buprenorphine reported significantly more withdrawal 
symptoms, and less positive opioid effects from their medication, than did subjects receiving 
methadone.  
 
A follow-up study to the trial comparing BNx and methadone was conducted a mean of 4.5 years 
post-randomization; 73% of participants were interviewed and asked to provide a urine sample (46). 
Opioid use at follow-up was significantly higher among participants originally randomized to BNx, 
mainly due to less participation in treatment. At follow-up, mortality was not different between the 
two randomized conditions. However, clinical trials may be underpowered to detect differences in 
mortality. A large data-linkage study from Australia (15) investigated mortality, and overdose 
mortality, in 32,033 people who had commenced methadone or buprenorphine. It confirmed a 
significantly higher death rate during induction onto methadone compared to buprenorphine, no 
difference during treatment, but in the month after leaving treatment, drug-related mortality was 
significantly lower for the methadone cohort (adjusted drug-related mortality rate ratio 0·50, 0·29–
0·86).  
 
New formulations: Long-acting buprenorphine and naltrexone formulations 
Enhancing retention in treatments for OUD, especially with naltrexone and buprenorphine, is key to 
improving long-term outcomes. One approach to improving adherence has been development of 
sustained-release preparations. Two depot injections of buprenorphine, and one buprenorphine 
implant, have been tested in clinical trials. One trial of depot buprenorphine compared it to 
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sublingual BNx, and reported the depot was not inferior (47). The second trial, using a different 
depot, reported it was superior to placebo (48). One trial of buprenorphine implants has been 
reported, demonstrating non-inferiority to sublingual BNx (49). Based on these studies, it is not 
possible to conclude that any of these depot preparations is superior in efficacy to the others, nor 
that depot preparations are superior to sublingual buprenorphine. In all trials of depot 
buprenorphine, more than half of urine samples were opioid positive in the active treatment groups, 
in part due to high drop-out rates.  
 
A sustained-release injectable formulation of naltrexone, designed to block opioid effects for 1 
month, was tested in an open-label trial. Opioid-dependent individuals were randomised to either 
sustained release naltrexone or sublingual BNx (50). There were more dropouts during induction in 
the naltrexone group (72%, compared to 94% in BNx). On an intention-to-treat analysis, relapse at 
24 weeks was 65% for naltrexone, and 57% for buprenorphine; this difference was attributable to 
induction failures. Among participants successfully inducted, 24-week relapse events were similar 
across study groups. Opioid-negative urine samples (p<0·0001) and opioid-abstinent days (p<0·0001) 
favoured BNx compared with the depot among the intention-to-treat population, but were similar 
across study groups among the per-protocol population. A smaller Norwegian trial (51) reported 
similar results, although on the retained-in-treatment comparison naltrexone was superior to BNx in 
suppressing heroin use.  
 
Overall, depot preparations of buprenorphine tested to date have not performed better than 
sublingual BNx. Retention in depot naltrexone was better than usually observed in studies using oral 
naltrexone, but not superior to sublingual BNx. As with all forms of treatment for OUD, the 
naltrexone depot probably does not avoid the risk of overdose after it ceases to deliver a therapeutic 
blood level, as there have been case reports of fatalities following naltrexone depot (52). 
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Comparing MAT with non-medical approaches to OUD 
Despite the limitations of MAT, it has distinct advantages over other approaches to treatment of 
OUD. An observational study from the US (53) looked at participation in MAT using Medicaid data on 
people aged 22 or less with a diagnosis of OUD. The end point was retention in treatment as shown 
by no Medicaid claims within 60 days. Early introduction of any medication was associated with 
better retention than drug-free approaches; median retention was 123 days in buprenorphine, 150 
days in naltrexone, 324 days in methadone, and 67 days among youths who received only behavioral 
health services. Medication assisted treatments were each independently associated with lower 
attrition from treatment compared with receipt of behavioral health services alone. This study has 
limitations, being non-randomised, and with an end-point that did not clearly identify how subjects 
were doing. However, it has the advantage of being a real-world study. Receipt of medication helped 
hold young people with OUD in treatment. Naltrexone and buprenorphine were similarly effective in 
retaining people, although not as effective as methadone.  
 
MAT in Pregnancy 
OUD during pregnancy is associated with many adverse outcomes, including an increased risk of 
stillbirth, prematurity, intrauterine growth retardation, and prolonged hospital stay post-delivery 
(54). Management of the pregnant woman with OUD is optimised by use of a coordinated, specialist 
team including social services, addiction medicine, obstetrics and neonatology (55). When used in 
conjunction with comprehensive care, methadone and buprenorphine have been demonstrated to 
improve treatment outcomes in pregnant women with OUD (56). The objective of medication 
management is to provide a stable intrauterine milieu, minimizing episodes of opioid intoxication 
and opioid withdrawal. Outcomes when methadone was continued throughout pregnancy were 
superior to those observed in women managed with methadone withdrawal during pregnancy (56).  
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Babies exposed to methadone in utero are at high risk of neonatal abstinence syndrome (NAS), 
characterised by irritability and autonomic dysfunction. Recent data demonstrates that 
buprenorphine is a safe alternative to methadone in pregnancy, and is associated with significantly 
lower severity of NAS (57). 
 
Whereas use of methadone and buprenorphine in pregnancy is now accepted, there is less 
experience with naltrexone in managing OUD in pregnancy. Opioid withdrawal during pregnancy is 
associated with increased risk of miscarriage and of fetal distress, making it risky to initiate 
naltrexone during pregnancy (58).  
 
Heroin assisted treatment 
In the mid-1990s, confronted with a heroin epidemic, Swiss clinicians introduced a highly structured 
treatment, involving the injecting of pharmaceutical heroin up to 3 times daily under direct 
observation (59). A subsequent series of randomised trials provided the evidence for this treatment. 
Pooled analysis of trials showed that more than half of apparently 'un-treatable' or poorly-
responding patients substantially disengage from use of street heroin within 6 months, with 
reductions in criminal involvement, and improvement in health and well-being (60). From these 
findings has emerged a new treatment modality, now available in Canada and some European 
countries – Heroin Assisted Treatment (HAT). Injected hydromorphone has also been trialled, and 
appears to be of similar efficacy as injected heroin (61). 
 
 
HAT is a treatment for individuals with injecting OUD who have failed to derive benefit from other 
treatments. It involves supervised injection of pharmaceutical heroin up to 3 times daily, with 
concurrent oral methadone (or other long-acting opioid) available to minimize withdrawal in the 
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inter-dosing intervals. The rationale for prescribing pharmaceutical heroin is to enable some 
individuals with the most entrenched addiction to stop use of illicit opioids, breaking the link with 
associated health risks and criminal activities. HAT patients often have histories of poor therapeutic 
relationships in previous treatments; trials demonstrate that with skilled staff to provide support 
and supervision, HAT can hold previously treatment-resistant subjects in structured treatment (62).   
 
The major adverse events associated with HAT are respiratory depression and seizures, both of 
which tend to occur within minutes after injection.  Pooled analysis from trials indicates that there 
was a significantly higher risk of serious adverse events linked to medication in the HAT groups 
compared to methadone groups, but no deaths attributable to prescribed medication, as overdoses 
were managed by supervising staff (60).  
 
RCTs are short-term studies, and give little indication about long-term outcomes. Much remains to 
be learned about the place of HAT in a treatment system. The cost is several times more than with 
buprenorphine or methadone maintenance (although not as expensive as long-term residential 
rehabilitation or prison); however, cost-benefit analyses have reported that HAT is cost-effective 
since other treatments deliver such poor results for these patients (63).  
 
Naloxone 
Naloxone is an opioid antagonist; intravenous or intramuscular naloxone promptly reverses opioid 
effects, and is routinely used to reverse opioid overdose. Pre-provision of a Take-Home Naloxone 
(THN) kit to injecting drug users, plus training the recipients in emergency management of the 
overdose situation, is an intervention being introduced in many countries. The objective is to reduce 
opioid overdose fatalities. The rationale is that most overdoses occur in the presence of others, with 
observers often taking actions (not always well-informed) to reverse overdose. Target populations 
have shown high levels of willingness to engage actively with emergency resuscitation.  
14 
 
 
THN projects report real-world emergency use of about 10% of naloxone distributed. Two recent, 
independently conducted Bradford-Hill public health analyses (64, 65) both concluded, on the basis 
of published evidence from a range of sources, that THN reduces the risk of fatal overdose. 
 
The development of new concentrated naloxone nasal sprays (three different products now in use 
globally) should increase the acceptability of wider THN. The unit dose used in ER and ambulance 
setting is 0.4mg, often administered intramuscularly, with repeat dosing as necessary. All THN kits 
include more than one dose (typically twin-pack).  The new naloxone nasal sprays deliver doses 
ranging from 1-4mg per spray with approximately 50% bioavailability (66).  
 
There remains much to be learned about use of THN. Differing local drug problems (such as fentanyl 
availability in North America) may mean that higher doses of naloxone are required. Higher doses of 
naloxone can precipitate withdrawal in dependent users, and so a dose-titration approach, starting 
with lower doses, is proposed by other countries (67). THN depends on competence by lay 
responders, and there are also differences in the importance attached to training. Some advocates 
concentrate on attention to respiratory depression and the provision of assisted breathing whilst 
others present much fuller training including cardiopulmonary resuscitation. THN schemes generally 
stress the importance of early ambulance call alongside assisted breathing. 
 
Cost often obstructs THN provision. In some countries, take-home naloxone kits are provided at no 
cost to the individual recipient, whereas other countries require the individual to meet the 
subsidised or full-price cost. Naloxone itself is cheap, with naloxone ampoules costing a dollar, 
whereas newer formulations can cost hundreds of dollars.  
 
Which medication for which patient? 
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There is consistent evidence for the greater pharmacological effectiveness of methadone in retaining 
people in structured treatment. The distinct advantages of buprenorphine and naltrexone is that 
they do not require daily attendance for supervised administration, making them valuable options 
for individuals who can benefit from less structured treatment. There is currently no evidence to 
predict which patient will do best with which medication. The main guide is patient preference. A 
flexible approach to treatment is optimal, adjusting medication and treatment conditions according 
to response. “Stepped care”, in which people commence treatment on buprenorphine can transfer 
promptly to methadone if not responding, has been demonstrated to be as effective as initiating 
treatment with methadone (68). A French study confirmed that individuals not responding to 
buprenorphine, who were transferred to methadone, had significantly improved outcomes (16). In 
people not responding to methadone, transfer to HAT can result in improved outcomes (60). 
 
Responding to the North American Opioid Epidemic  
North America is in the grip of an “opioid crisis”. Escalating opioid overdose deaths are attributable 
to overlapping epidemics – a longer-phase epidemic of prescription opioid use with associated 
deaths, a more recent epidemic of illicit heroin use and mortality, and most recently a sharp-onset 
epidemic of use of illicitly-manufactured fentanyl. Age-standardised mortality rates for fentanyl, 
fentanyl analogues, and tramadol were 0.3 per 100,000 in 1999, 1.0 in 2013, 1.8 in 2014, 3.1 in 2015, 
and 6.2 in 2016. In contrast, mortality rates for heroin increased from 0.7 in 1999, to 1.0 in 2010, to 
4.9 in 2016; and from methadone, ranged from 0.3 in 1999 to 1.8 in 2006, and 1.0 in 2016 (69).  
 
OUD underlies the growing opioid overdose crisis in North America. Opioid overdose deaths could 
be reduced by ensuring people with OUD have access to treatment that is affordable, and of 
adequate quality such that patients remain and have a greater likelihood of good outcomes (70). In 
the current North American opioid epidemic, there is a lack of treatment spaces. For two decades US 
authorities have sought to expand treatment, particularly buprenorphine treatment. However, in 
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2012, a decade after treatment expansion began, it was estimated that the maximal potential 
availability of methadone or buprenorphine treatment was about 60% of the number of individuals 
with OUD (71); and actual availability fell well short of potential. About half of DATA-waived 
physicians actually prescribed buprenorphine; of these prescribers, the majority did not prescribe to 
their maximum patient limit. A further recent response has been the much wider provision of take-
home naloxone so that, when overdose occurs, fatal outcome can be avoided, and the FDA is now 
considering whether emergency naloxone packs should be co-prescribed with some or all opioid 
prescriptions (72). 
 
Conclusion 
Methadone has the best evidence for effectiveness; buprenorphine and naltrexone also have 
evidence of effectiveness and provide distinct different benefits and are important treatment 
options. Evidence of whether the new, sustained-release formulations of buprenorphine and 
naltrexone bring distinct advantage is not yet available.  Some people with injecting OUD and a poor 
response to conventional treatments can benefit from the more intensive treatment of HAT. 
Provision of naloxone to people not currently in treatment may be one measure to reduce the 
overdose toll.  
 
Expanding access to methadone treatment, through allowing methadone prescribing in primary care 
and dispensing in pharmacies, has been proposed as the most useful approach to expanding access 
to effective treatment in the US, where currently methadone treatment is more highly restricted 
than in many other countries (73). Based on the greater pharmacological efficacy of methadone in 
holding people in treatment, this seems a timely recommendation.   
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